Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. KISPLYX (lenvatinib)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

KISPLYX (lenvatinib)

Medicine - Posted on Mar 22 2022
Active substance (DCI)
  • lenvatinib
history (2)
  • Economic analysis
    2/2/22

    KISPLYX (lenvatinib)

    Key points Favourable opinion for reimbursement of KISPLYX (lenvatinib) in combination pembrolizumab in the first-line treat...
    CAV :
    54321
    icône flèche
  • 2/2/22

    KISPLYX (lenvatinib) (cancer du rein uniquement à cellules claires)

    Nouvelle indication Avis favorable au remboursement de KISPLYX (lenvatinib) en association au pembrolizumab dans le traiteme...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01EX08
Manufacturer
ESAI S.A.S.
Presentation

KISPLYX 4 mg, gélule
Boîte de 30 gélules - (Code CIP : 340 09 300 749 54)

KISPLYX 10 mg, gélule
Boîte de 30 gélules - (Code CIP : 340 09 300 749 61)

All our publications
    Drug therapy Urologic cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
HSwBR0nr8CDJmSgA